Genomics

Dataset Information

0

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy [ID8 and ID8-IP / KMF cells]


ABSTRACT: Gene copy number changes, cancer stem cell (CSC) increases, and platinum chemotherapy resistance contribute to poor prognosis in patients with recurrent high grade serous ovarian cancer (HGSOC). CSC phenotypes involving Wnt-b-catenin and aldehyde dehydrogenase activities, platinum resistance, and tumor initiating frequency are here associated with spontaneous genetic gains, including genes encoding KRAS, MYC and FAK, in a new murine model of ovarian cancer (KMF). Noncanonical FAK signaling was sufficient to sustain human and KMF tumorsphere proliferation, CSC survival, and platinum resistance. Increased FAK tyrosine phosphorylation occurred in HGSOC patient tumors surviving neo-adjuvant platinum and paclitaxel chemotherapy and platinum resistant tumorspheres acquired FAK dependence for growth. Importantly, combining a pharmacologic FAK inhibitor with platinum overcame chemoresistance and triggered apoptosis in vitro and in vivo. Knockout, rescue, genomic and transcriptomic analyses collectively identified more than 400 genes regulated along a FAK/b-catenin/Myc axis impacting stemness and DNA repair in HGSOC, with 66 genes gained in a majority of Cancer Genome Atlas samples. Together, these results support combinatorial testing of FAK inhibitors for the treatment of recurrent ovarian cancer. Overall design: mRNA profiles of ID8 and ID8-IP / KMF cells were generated in triplicate using an Illumina NovaSeq 6000 Sequencing System

INSTRUMENT(S): Illumina NovaSeq 6000 (Mus musculus)

ORGANISM(S): Mus musculus  

SUBMITTER: David D Schlaepfer  

PROVIDER: GSE129097 | GEO | 2019-07-01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
GSE129097_Id8ip_vs_Id8_DEG_all.txt.gz Txt
Items per page:
1 - 1 of 1

Similar Datasets

2019-07-01 | GSE129098 | GEO
2019-01-01 | S-EPMC6721800 | BioStudies
1000-01-01 | S-EPMC4695147 | BioStudies
| PRJNA530133 | ENA
2018-03-31 | E-MTAB-4663 | BioStudies
| S-EPMC3622195 | BioStudies
2019-01-01 | S-EPMC6935502 | BioStudies
| S-EPMC7236773 | BioStudies
2019-01-01 | S-EPMC6547556 | BioStudies
2019-01-01 | S-EPMC6946301 | BioStudies